12:31 PM EDT, 09/03/2025 (MT Newswires) -- Artelo Biosciences ( ARTL ) said Wednesday that interim data from a phase 2 study of ART27.13 to treat cancer anorexia-cachexia syndrome were "highly encouraging," with treatment resulting in consistent improvements in weight gain, lean body mass, and activity.

The company said patients achieved a roughly 6.4% mean weight gain after 12 weeks, compared with a 5.4% weight loss on placebo. Patients also achieved a 4.2% increase in lean body mass, compared with 3.2% loss on placebo, the company added,

The drug was well tolerated with no new safety signals and no drug-related serious adverse events, although there was a single case of severe malaise, according to a statement.

Separately, the company said it was in talks with potential development partners for ART27.13, adding that a licensing deal could be a value-accretive path for stockholders.

Shares of the company fell more than 6% in recent trading Wednesday.

Price: 8.63, Change: -0.57, Percent Change: -6.20